Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Inverness Buys Rapid Tests from Abbott for $92.5 Million

By HospiMedica staff writers
Posted on 20 Oct 2003
The acquisition of certain rapid tests and intellectual property, excluding the Determine products, from Abbott Laboratories (Abbot Park, IL, USA) for about US$92.5 million in cash and stock has been announced by Inverness Medical Innovations, Inc. More...
(Waltham, MA, USA).

Under the agreement between the two companies, Inverness has acquired assets related to the Fact plus pregnancy test and the Abbott TestPack, TestPack plus, and Signify lines of rapid diagnostics for testing strep throat, pregnancy, and drugs of abuse. The assets also include certain transferred and licensed intellectual property related to the products. Abbott will provide transitional service, including limited manufacturing, for up to 18 months. Also, Abbott will retain exclusive distribution rights for TestPack and Signify in the United States except in physician office laboratories currently served by PSS World Medical. Inverness will assume worldwide distribution of the Fact plus test.

The acquisition is a continuation of the efforts of Inverness to expand in the field of rapid diagnostics, the company stated. "We expect to benefit from product and distribution synergies with our current rapid diagnostic business,” said Ron Zwanziger, CEO of Inverness Medical Innovations.





Related Links:
Abbott
Inverness

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.